TCRX
MaterialsTscan Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving TCRX Today?
No stock-specific AI insight has been generated for TCRX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
TCRX News
20 articles- TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 6, 2026
- TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 6, 2026
- TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual MeetingYahoo Finance·Apr 27, 2026
- TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire Inc.·Apr 8, 2026
- Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy SpaceYahoo Finance·Mar 25, 2026
- TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 4, 2026
- TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 4, 2026
- TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03Yahoo Finance·Feb 26, 2026
- Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Feb 25, 2026
- TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 25, 2026
- Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Feb 12, 2026
- Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?Yahoo Finance·Feb 11, 2026
- Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue EstimatesYahoo Finance·Feb 6, 2026
- TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and ExpositionYahoo Finance·Dec 6, 2025
- TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market OpportunitiesYahoo Finance·Dec 3, 2025
- TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue EstimatesYahoo Finance·Nov 12, 2025
- TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 12, 2025
- Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue EstimatesYahoo Finance·Nov 10, 2025
- Novavax (NVAX) Reports Q3 Loss, Beats Revenue EstimatesYahoo Finance·Nov 6, 2025
- Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance·Nov 5, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Tscan Therapeutics Inc
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.